**Name of journal: World Journal of Anesthesiology**

**ESPS Manuscript NO: 5111**

**Columns: Original Articles**

**Paroxetine *vs* pregabalin for the management of neuropathic pain in multiple sclerosis**

Turcotte DA *et al*. Paroxetine *vs* pregabalin for neuropathic pain

Dana A Turcotte, Malcolm Doupe, Mahmoud Torabi, Andrew J Gomori, Karen Ethan, Farid Esfahani, Katie Galloway, Michael P Namaka

**Dana A Turcotte, Michael P Namaka,**Faculty of Pharmacy, University of Manitoba, Winnipeg, Manitoba R3E 0T5, Canada

**Malcolm Doupe,** Manitoba Centre for Health Policy, Winnipeg, Manitoba R3E 3P5, Canada

**Mahmoud Torabi,** Department of Community Health Sciences, Faculty of Medicine, University of Manitoba, Winnipeg, Manitoba R3E 3P5, Canada

**Andrew J Gomori,** Section of Neurology, Faculty of Medicine, University of Manitoba, Winnipeg, Manitoba R3T 2N2, Canada

**Karen Ethans, Michael P Namaka,** Section of Physical Medicine and Rehabilitation, University of Manitoba, Winnipeg, Manitoba R3A 1R9, Canada

**Farid Esfahani,** Winnipeg Clinic, Winnipeg, Manitoba R3C 0N2, Canada

**Katie Galloway,** Department of Statistics, University of Manitoba, Winnipeg, Manitoba R3T 2N2, Canada

**Michael P Namaka,** Department of Human Anatomy, Faculty of Medicine, University of Manitoba, Winnipeg, Manitoba R3E 0J9, Canada

**Author contributions:** Turcotte DA, Namaka MP, Doupe M and Torabi M were involved in study design and initial planning; Turcotte DA, Namaka MP, Esfahani F, Gomori AJ and Ethans K were involved in acquisition of patient data; Turcotte DA, Doupe M, Torabi M and Galloway K were responsible for data analysis and interpretation; Turcotte DA wrote the original manuscript draft; Turcotte DA, Namaka MP, Ethans K, Esfahani F, Galloway K, Torabi M, Gomori AJ and Doupe M critically reviewed and revised content; all listed authors approved final version of this manuscript for publication.

**Correspondence to: Dr. Dana A Turcotte,** Faculty of Pharmacy, University of Manitoba, 750 McDermot Avenue, Winnipeg, Manitoba R3E 0T5, Canada. danaturcotte19@gmail.com

**Telephone:** +1-204-2955358 **Fax:** +1-204-4747617

**Received:** August 15, 2013 **Revised:** June 12, 2014

**Accepted:** June 14, 2014

**Published online:**

**Abstract**

**AIM:** To compare the effectiveness and tolerability of paroxetine *vs* pregabalin for the management of multiple sclerosis (MS)-induced neuropathic pain (NPP).

**METHODS:** A randomized, flexible-dose open-label 8-wk study involving 21 relapsing-remitting MS patients with MS-induced NPP was conducted to evaluate the effectiveness and tolerability of pregabalin versus paroxetine for pain management. The trial included a 3-wk dose titration phase followed by a 5-wk stable dose phase. Primary outcome measures included daily patient-reported pain intensity as measured using a 100 mm visual analogue scale (VASpain) and daily impact of pain on daily activities (VASimpact). Hierarchical regression modeling was conducted on each outcome to determine if within person VAS trajectory for pain and impact differed across study groups, during 56 d follow-up.

**RESULTS:** Attrition rates were significantly greater (*P* < 0.001) in the paroxetine versus pregabalin study group (70% *vs* 18.2%, respectively). Average study duration between study groups also significantly differed (*P* < 0.001). Paroxetine participants completed an average of 27.3 d of treatment *vs* 49.5 d in the pregabalin group, with the majority of patients withdrawing due to adverse events. Due to the high attrition rates in the paroxetine study arm, the investigators stopped the study prior to achieving complete recruitment. As such, no significant differences between pregabalin and paroxetine study arms were noted for the primary outcome measures (VASpain,VASimpact). Comparative assessment of baseline patient characteristics also revealed no significant differences between the study arms.

**CONCLUSION:** High attrition rates associated with paroxetine use suggest that it be used with caution for MS-induced NPP. Efficacy outcomes could not be assessed due to attrition.

© 2014 Baishideng Publishing Group Inc. All rights reserved.

**Key words:** Multiple sclerosis; Neuropathic pain; Paroxetine; Pregabalin; Clinical trial

**Core tip:** The high attrition rates identified in the paroxetine study arm suggest that it be used with caution for multiple sclerosis (MS)-induced neuropathic pain (NPP). Although analysis of the primary endpoint measures revealed no significant differences, there was a trend toward marked improvement for visual analogue scale and daily impact of pain on daily activities in favor of pregabalin. However, due to the premature study cessation, definitive confirmation of pregabalin’s enhanced efficacy was not possible. These results reinforce the recognized challenges clinicians encounter in drug selection for MS-induced NPP. Due to the lack of well-designed controlled NPP trials in this population, effective and well-tolerated treatment selection poses a significant clinical challenge.

Turcotte DA, Doupe M, Torabi M, Gomori AJ, Ethan K, Esfahani F, Galloway K, Namaka MP.Paroxetine *vs* pregabalin for the management of neuropathic pain in multiple sclerosis. *World J Anesthesiol* 2014; In press

**INTRODUCTION**

Multiple sclerosis (MS) is a chronic, neurodegenerative disease that affects over two million people world-wide[1]. Pain is recognized as one of the most significant MS-induced symptoms. It has been reported that up to 80% of MS patients experience some form of chronic pain[2-5]. MS-induced neuropathic pain (NPP) is a chronic pain syndrome caused by damage to the nerve fibers involved in the synaptic transmission of pain. Hallmark clinical symptoms include sensory abnormalities such as: numbness, burning, feeling of pins and needles, tingling sensations and shock-like pain[6,7].

At present, there is no cure for MS-induced NPP. Henceforth, treatment goals are focused primarily on reducing pain to a more tolerable level. Patients with NPP often suffer other co-morbidities such as mood and sleep disorders[8,9]. Clinicians are therefore faced with the additional challenge of selecting a therapeutic option capable of managing all these domains associated with chronic pain. For example, antidepressant medications possess a distinct advantage of having analgesic and antidepressant/sedative properties that assist with both pain, mood and sleep issues. As such, tricyclic antidepressants (TCAs), such as amitriptyline and nortriptyline, are recommended as first-line agents for NPP[10]. TCAs elicit their analgesia through the pre-synaptic reuptake inhibition of serotonin (5-HT) and norepinephrine (NE), thereby enhancing descending pain modulating pathways[11]. In addition, TCAs have also been shown to exhibit sodium and calcium channel blockade, resulting in decreased neuronal hyperexcitability[11]. Despite documented effectiveness in various NPP conditions, the usefulness of TCAs in MS is often limited due to poor tolerability[11]. MS patients often suffer a variety of disease-induced symptoms that include: dizziness, ataxia, bladder/bowel retention, drowsiness and fatigue. These underlying disease induced symptoms can all be potentially intensified by the addition of a TCA to their medication regimen. As such, it many cases, it is difficult to attain therapeutic dosages to successfully control their pain.

Selective serotonin reuptake inhibitors (SSRIs) are antidepressant medications that may be better tolerated in individuals with MS due, in part, to the lack of anticholinergic effects. SSRIs selectively block the pre-synaptic reuptake of 5-HT, resulting in an accumulation of 5-HT in synapses involved in the transmission of pain. As such, analogous to TCA’s, SSRIs are suggested to have an analgesic role via potentiating the descending pain inhibitory mechanisms[12]. Interestingly, a recent animal model evaluating the analgesic effects of the SSRI paroxetine suggests an additional mechanistic link to produce analgesia *via* opioid systems[13]. Although limited, there is some evidence supporting the analgesic efficacy of SSRIs in NPP. In two randomized, placebo controlled trials, citalopram[14] (*n* = 17) and paroxetine[15] (*n* = 20) were both found to be effective at reducing pain intensity associated with diabetic peripheral neuropathy (DPN) when comparatively assessed against placebo. Citalopram, dosed at 40 mg daily, was found to significantly reduce self-reported pain intensity (*P* = 0.007), and was well-tolerated with two individuals receiving active treatment withdrawing early due to adverse events (nausea and vomiting, gastric upset)[14]. Paroxetine evaluated for DPN in a placebo-controlled cross-over design at a dosage of 40 mg daily was found to be significantly better at reducing self-reported pain intensity than placebo (*P* = 0.012)[15]. No individuals receiving paroxetine in this trial withdrew early. Although, paroxetine has been evaluated for depression in MS[16], to the best of our knowledge, it has not been evaluated for MS-induced NPP.

In addition to antidepressants, several other first-line agents have been used in the treatment of NPP, including pregabalin[10]. Pregabalin is an anticonvulsant medication thought to elicit analgesic effects through interaction with the α2δ subunit of N-type voltage-dependent Ca2+ channels, ultimately reducing overall neuronal excitability[17]. Several large controlled trials have demonstrated consistent efficacy results for use in post-herpetic neuralgia (PHN) and diabetic peripheral neuropathy (DPN)[18-20]. Formal evaluation of pregabalin for use in MS-induced NPP, however, is limited. One open-label pilot study evaluating the effect of pregabalin (mean dosage 154 mg daily) on paroxysmal painful symptoms in MS (*n* = 16) found it to be both efficacious at reducing pain from time 0 to one month follow-up (*P* < 0.05) and well-tolerated[21].

At present, few drugs are approved specifically for MS-induced NPP[22]. In fact, MS-induced NPP is often managed by the off label use of medications. Hence, outcome measures of efficacy and tolerability in clinical trials focused on NPP resulting from diabetes, herpes zoster or injury, are often employed to drive therapeutic decision-making in the MS population. Due to the lack of focused research specifically evaluating therapies for MS-induced NPP, we have undertaken a study aimed to evaluate the efficacy and tolerability of paroxetine and pregabalin for the management of NPP in individuals with relapsing-remitting MS (RRMS). We hypothesize that pregabalin would significantly reduce daily absolute pain when compared to paroxetine with similar tolerability. To our knowledge, this is the first study to formally compare these agents for the management of NPP in RRMS.

**MATERIALS AND METHODS**

A randomized, open-label, parallel pilot study was conducted at the MS clinic of the Health Sciences Centre in Winnipeg, Manitoba, Canada over a 4 year period. Ethical approval for this study was obtained by the Biomedical Research Ethics Board of the University of Manitoba. Study procedures adhered to practices outlined in Good Clinical Practice Guidelines. Based on stringent enrolment criteria, eligible patients providing written informed consent were enrolled for participation into the trial. Eligibility inclusion criteria comprised: (1) males and females between the ages of 18-65 years old, (2) clinically definite RRMS, as defined by the McDonald Criteria[23], (3) Expanded Disability Status Scale (EDSS) score of < 6.0 (*i.e.*, not restricted to a wheelchair)[24], (4) no concurrent MS relapse at time of enrolment, and (5) Visual Analogue Scale (VAS) score for NPP symptoms ≥ 5 with pain symptoms present for at least 3 mo prior to enrolment. Eligibility exclusion criteria comprised: (1) pregnancy or breastfeeding, or immediate conception plans, (2) known history of alcohol and/or substance abuse, (3) history of non-psychotic emotional disorders, (4) significant hepatic and/or renal insufficiency that would require dose adjustments of study medications, (5) significant cardiovascular disease (congestive heart failure, cardiac rhythm abnormalities) and/or uncontrolled hypertension (systolic blood pressure ≥ 140 mmHg, diastolic blood pressure ≥ 90 mmHg), (6) documented hypersensitivity to paroxetine or pregabalin or any of their derivatives, and (7) current medications with potential significant interactions with study meds (as determined by clinical pharmacist). In addition, patients were allowed to remain on current pain medications provided medications have been at stable dosages for at least 6 mo and must not interact with study medications. Please refer to Table 1 for a complete summary list of all the inclusion and exclusion criteria.

All eligible, consenting patients were randomized to receive treatment with either paroxetine or pregabalin. Randomization assignments, completed by an individual independent of the study, were generated using pre-programmed computer software (Microsoft Excel®) employing a random permuted blocks approach[25]. To minimize the ability to predict subsequent treatment assignments, it was selected to also randomize the block sizes, varying them as either 2 or 4 patients per block. Results of the randomization generation were placed within opaque envelopes numbered sequentially. After all pre-screening and consenting procedures were done, the subsequent treatment assignment envelope was opened and randomization result provided.

Once randomized to drug treatment, patients completed a physician-conducted baseline screening (Baseline Assessment), during which they underwent baseline physical and neurological examinations. Additionally, patients were provided with a Daily Pain Diary (DPD), required for daily self-completion to monitor the intensity and impact of pain. Patients were instructed to record their daily pain score upon waking each morning in the DPD provided to them. The DPD was comprised of a vertical VAS scale of 0 mm (no pain) to 100 mm (worst pain imaginable) and patients were required to record their daily pain score (intensity) over the previous 24 h (VASpain). In addition, the DPD contained a second identical vertical VAS scale to evaluate the impact of daily pain on their daily activities (VASimpact), anchored this time with 0 mm (no effect) to 100 mm (incapacitating). At the end of the baseline assessment, patients were provided with dosing instructions for the subsequent three-week “titration period”.

Dosing instructions were dependent on treatment assignment, and included three possible weekly increases. Patients were contacted by phone prior to the initiation of the subsequent dosage step. If patients were experiencing significant adverse events or ≥ 50% pain relief at the current dose, in collaboration with the patient, it was within the clinician’s discretion to halt dosage increases and instruct individuals accordingly. Please refer to Table 2 for a summary of the suggested dosage schedule.

Patients were required to return to the clinic for an adverse event assessment at the end of the “titration phase” (Post-Titration Assessment). At this time, patients completed a standardized “Adverse Event Checklist” containing a word-list of possible side effects to document any current or previously experienced symptoms since beginning the study. To minimize prompting, passive collection of adverse events was facilitated through the inclusion of adverse event descriptors of known association to the study drugs and those of less common or unknown association, in random order. At the end of the post-titration assessment the current dose that the patient was able to attain by the end of the titration phase was entered as their stable dose for the subsequent 5-wk “maintenance phase”. DPD recording continued over the 5-wk maintenance phase. At the end of the maintenance phase patients returned to clinic for one final visit (Final Assessment) where they completed the same Adverse Event Checklist. Additionally at this time, patients were required to complete the Patient-Rated Global Impression of Change (PGIC). This tool is used to evaluate the patient’s perception of their assigned treatment on their pain symptoms. Patients were asked to rate their overall pain at this time point in comparison to their pain at the baseline assessment. Selection options included: (1) very much improved (2) much improved (3) minimally improved (4) no change (5) minimally worse (6) much worse (7) very much worse. The PGIC is well-validated for assessing patient perception on clinical treatment outcomes[26]. Please refer to Figure 1 for a summary of the clinical trial timeline.

***Statistical analysis***

Baseline patient covariates were compared for group differences using either an independent t test for continuous measures or a chi-squared test for the categorical measure (patient sex). Daily VASpain and VASimpact data exist at two levels (time and person), therefore a hierarchical model was used to assess the rate of within person change in these outcomes, differences in these outcomes across study groups collapsed across all times, and most importantly, group\*time interactions to determine if the rate of change in VASpain and VASimpact differed significantly by group[27]. All data analyses were conducted using R Software (2013)[28].

***Sample size calculation***

The required sample size in each treatment group was calculated based on the procedure outlined by Diggle *et al*[29]. It was assumed that the treatment allocation and baseline differences accounted for at least 13% of the total variation in daily VAS, which corresponds to a medium effect size defined by Cohen[30]. As well, there were 56 repeated measures for each subject with alpha set at 0.05 and the power was set at 0.8. Predicted drop-out was determined from results of previous clinical trials (pregabalin average 15.5%[31,32], paroxetine 19%[33]). The drop-out rates were accounted for using the method described by Sakpal (2010)[34]. Therefore, it was found that there should be a sample size of approximately 24 subjects would be required (12 in each study arm).

**RESULTS**

Collectively, 30 patients were screened for enrolment into the trial, prior to early closure of the study due to high drop-out rates. Of these patients, 7 were found to be ineligible based on inclusion/exclusion criteria (Table 1) and two were eligible but elected not to participate. Ultimately, 21 patients consented and were enrolled for participation in the study (10 randomized to paroxetine and 11 to pregabalin). No significant differences were noted between the groups on any of the baseline cohort characteristics collected. This information is summarized in Table 3.

Significant differences (*P* < 0.001) in attrition rates were identified between the two study groups that favored the pregabalin treatment arm. Specifically, in the pregabalin study arm, a total of 2 patients (18.2%) did not complete the entire 8-wk duration of the study. Conversely, assessment of the paroxetine study arm identified 7 patients (70%) that were not able to complete the study. The average percentage of maximum dosage was compared by study arm and did not differ significantly. This information is summarized in Table 3. Both patients who withdrew early in the pregabalin study arm did so as a result of intolerable sedation and dizziness. Attrition reasons for the paroxetine arm are summarized in Figure 2, with the most commonly reported attrition reasons being tremor, nausea and feelings of nervousness. Figure 3 illustrates drop-out as a survival plot. In comparing the average study duration (days) by study group, paroxetine was found to have a significantly lower mean than pregabalin (27.3 d *vs* 49.5 d, respectively, *P* < 0.01). This information is presented in Table 4.

Primary outcome measures were compared between the groups, with univariate modeling for VASpain and VASimpact demonstrating all non-significant findings. These results are presented in Table 5. Comparative assessment of 8 wk trial data involving patient-perceived treatment effect, (evaluated using the PGIC), revealed no statistically significant differences between treatment arms.

**DISCUSSION**

Individuals with MS can be plagued by many unique disease-induced symptoms not commonly seen in other NPP conditions, including: ataxia, dizziness, cognitive impairment, imbalance, bladder/bowel dysfunction and visual disturbances. Many of the current first-line treatment recommendations from general NPP guidelines have the potential to induce drug-related adverse effects that can mimic and worsen MS disease symptoms. As such, tolerability limitations must be considered when translating general NPP guideline recommendations to MS-induced NPP clinical management. This is made evident by the outcomes of the current trial, which indicated a significantly high attrition rate in those patients treated with paroxetine versus pregabalin (*P* < 0.001). The results of our study in this specific patient population contradicts the favorable tolerability of paroxetine in reported in other clinical pain trials, such as burning mouth syndrome[33] and DPN[15]. Our results suggest that due to other underlying disease induced symptoms commonly associated with MS, paroxetine may not be the most suitable choice for this patient population. Furthermore, the combination of stringent enrollment criteria and recognized high attrition rates hindered patient enrollment for this study. As result, the reduced sample size prevented optimal assessment of the proposed primary study aims developed to assess efficacy.

Irrespective of these challenges, the primary outcome measures (VASpain and VASimpact) were compared univariately revealing no significant difference between groups. In addition, patient-perceived treatment benefit–as determined by the PGIC at the Final Assessment–did not differ significantly between the groups, reinforcing the equivocal results of this trial. Due to the high attrition rate in the paroxetine study arm, comparison of primary outcomes between the groups is compromised due to small numbers of patients remaining after the mid-point of the study. As such, comparison results must be interpreted cautiously as the ability to detect any potential differences is greatly restricted.

In addition to the high attrition and resultant reduced study power, our study is not without further limitations that may impact interpretation of results. Our study was developed as an open-label design. As a result of patient’s awareness of active treatment, psychosomatic contributions may have contributed to any primary outcome effects. Although blinding and controlling for bias through inclusion of a placebo arm would have undoubtedly strengthened the power of the study ethical restraints prevented study blinding as neither of the comparative agents selected for the study had approved indication from Health Canada for MS-induced NPP. As a result, this aspect of study design was not incorporated to ensure complete transparency in that the enrolled patients were fully informed of the use of an off-label medication to manage their pain.

MS presents an especially challenging disease to effectively manage NPP. This in part is not only due to confounding disease-induced symptoms, but also due to the polypharmacy that is often observed in this population. Individuals with MS are often on multiple medications to manage the multifaceted nature of their primary disease. As such, NPP treatment options are further limited due to potential drug interactions and/or therapeutic class duplication issues. These unique treatment considerations make simply applying current general NPP guidelines directly to MS care inappropriate. Most guidelines for NPP are created based on large-scale studies in various other NPP conditions, such as DPN and post-herpetic neuralgia. Although, mechanistically, it is likely that current first-line agents for NPP would target the underlying pain mechanisms of MS-induced NPP, the inability to tolerate these medications and achieve therapeutic dosages can be significantly hindered. The only way to appropriately apply guideline recommendations to this unique patient population is by first validating their efficacy and tolerability in these patients in accordance with a randomized, controlled setting. Unfortunately, data from randomized clinical trials (RCTs) for MS-induced NPP is significantly lacking. Until the need for well-designed RCTs in MS-induced NPP is met, clinicians managing pain in this patient population must first consider tolerability issues of therapy rather than relying solely on the general NPP guidelines that encompass all patients with NPP irrespective of origin. In order to optimize treatment success, careful review of patient-reported disease-induced symptoms must be completed to determine which medications being considered for NPP would have the lowest likelihood of aggravating these underlying complaints. Additionally, a thorough review of concomitant medications would also be of benefit. Once an appropriate treatment is selected, a conservative dosage titration schedule should be followed in order to minimize adverse events and prevent drug interactions with existing therapy. Frequent follow-up to facilitate communication between clinician and patient should be established to ensure that realistic treatment goals as well as realistic timelines for these outcomes are met.

In summary, due to the high attrition rates observed in this study resulting in premature closure, primary pain outcomes could not be appropriately assessed. Paroxetine, which has been found to be well-tolerated and effective for other chronic pain conditions, has been found poorly tolerated in this study. These results suggest that paroxetine should be used cautiously in those with MS-induced NPP. The unique tolerability issues observed in individuals with MS-induced NPP make the application of general therapeutic NPP guidelines inappropriate for many in this population, without consideration of additional disease-induced factors that may affect drug safety. Available guidelines are helpful tools for clinicians, however cannot be considered absolute due to unique needs of individuals in an MS population. Expert clinical judgement appropriately considering the therapeutic requirements of this population along with evidence-based data from other NPP states is therefore required, as it is unlikely that evidence-based guidelines specific to MS-induced NPP will be developed due to the lack of RCTs in this population. Collaborative communication between clinicians specialized in both MS care and pain management would ultimately improve therapeutic selection, implementation and follow-up resulting in improved tolerability and efficacy outcomes.

**COMMENTS**

***Background***

Neuropathic pain is a painful condition that can result from a number of different pathophysiological and disease-induced causes, and can be significantly challenging to control for many individuals. The majority of neuropathic pain management guidelines available to guide patient care are based upon larger scale pharmacotherapeutics trials in the more prevalent neuropathic pain conditions, including diabetic peripheral neuropathy, post-herpetic neuralgia and trigeminal neuralgia. Multiple sclerosis (MS) is a chronic, progressive neurological condition that can frequently result in the development of neuropathic pain. Due to the often complicated presentation of co-morbid disease-induced symptoms, treatment of neuropathic pain in individuals with MS can be challenging due to poor tolerability of first-line agents. Clinical trials specific to the MS population with neuropathic pain are rare, however they are essential in order to better understand safety and efficacy in this unique patient population. Both the antidepressant and antiepileptic classes of medication are used as first-line agents for many neuropathic pain conditions, however their efficacy and tolerability in individuals with MS-induced neuropathic pain are not well-studied.

***Research frontiers***

Paroxetine is a selective serotonin reuptake inhibitor antidepressant. Antidepressants are currently touted as first-line agents for the management of painful neuropathies not only based on their analgesic effects but also their effect on co-morbid mood and sleep issues often associated with chronic pain. Pregabalin is an antiepileptic and antineuralgic medication that is relatively new to the market and is also recommended as a first-line agent for the management of neuropathic pain.

***Innovations and breakthroughs***

Most clinical trials evaluating the efficacy and tolerability of specific medications for effects in various neuropathic pain conditions look at the effect of a specific agent against a placebo comparator. Although this is important to establish treatment effect, it does not allow us to differentiate between the various first-line agents. Additionally, very few clinical trials evaluating therapy for neuropathic pain in individuals with MS have been conducted. In an attempt to provide some initial information on the management of neuropathic pain in this patient population the authors have conducted a head-to-head clinical trial comparing paroxetine *vs* pregabalin to assess both efficacy and tolerability in this understudied patient group.

***Applications***

The results of this study provide us initial insight regarding the use of “first-line” agents in the management of neuropathic pain. The high rate of intolerability in the paroxetine treatment arm was surprising based on literature use in other patient populations. This reinforces to clinicians that individuals with MS present unique and complex clinical cases that may limit the use of agents considered “first-line” in other painful neuropathies.

***Terminology***

MS-induced neuropathic pain (NPP) is a chronic pain syndrome caused by damage to the nerve fibers involved in the synaptic transmission of pain. Pregabalin is an anticonvulsant medication thought to elicit analgesic effects through interaction with the α2δ subunit of N-type voltage-dependent Ca2+ channels, ultimately reducing overall neuronal excitability. Paroxetine is a selective serotonin reuptake inhibitor that selectively blocks the pre-synaptic reuptake of 5-HT, resulting in an accumulation of 5-HT in synapses involved in the transmission of pain.

***Peer review***

The primary aim was to compare the analgesia effect and improve of quality of daily life quality by the administration of Paroxetine and Pregabalin in neuropathic pain patients with MS. The study was well designed and written given the consideration of various factors confounding in this particular patients population.

**REFERENCES**

1 **WHO.** Atlas Multiple Sclerosis Resources in the World 2008. Albany, NY, USA: WHO; 2008

2 **Osterberg A**, Boivie J, Thuomas KA. Central pain in multiple sclerosis--prevalence and clinical characteristics. *Eur J Pain* 2005; **9**: 531-542 [PMID: 16139182 DOI: 10.1016/j.ejpain.2004.11.005]

3 **Bennett MI**, Bouhassira D. Epidemiology of neuropathic pain: can we use the screening tools? *Pain* 2007; **132**: 12-13 [PMID: 17888575 DOI: 10.1016/j.pain.2007.09.003]

4 **Ehde DM**, Gibbons LE, Chwastiak L, Bombardier CH, Sullivan MD, Kraft GH. Chronic pain in a large community sample of persons with multiple sclerosis. *Mult Scler* 2003; **9**: 605-611 [PMID: 14664474 DOI: 10.1191/1352458503ms939oa]

5 **Svendsen KB**, Jensen TS, Overvad K, Hansen HJ, Koch-Henriksen N, Bach FW. Pain in patients with multiple sclerosis: a population-based study. *Arch Neurol* 2003; **60**: 1089-1094 [PMID: 12925364 DOI: 10.1001/archneur.60.8.1089]

6 **Namaka M**, Gramlich CR, Ruhlen D, Melanson M, Sutton I, Major J. A treatment algorithm for neuropathic pain. *Clin Ther* 2004; **26**: 951-979 [PMID: 15336464 DOI: 10.1016/s0149-2918]

7 **Magrinelli F**, Zanette G, Tamburin S. Neuropathic pain: diagnosis and treatment. *Pract Neurol* 2013; **13**: 292-307 [PMID: 23592730 DOI: 10.1136/practneurol-2013-000536]

8 **Alba-Delgado C**, Llorca-Torralba M, Horrillo I, Ortega JE, Mico JA, Sánchez-Blázquez P, Meana JJ, Berrocoso E. Chronic pain leads to concomitant noradrenergic impairment and mood disorders. *Biol Psychiatry* 2013; **73**: 54-62 [PMID: 22854119 DOI: 10.1016/j.biopsych.2012.06.033]

9 **Schuh-Hofer S**, Wodarski R, Pfau DB, Caspani O, Magerl W, Kennedy JD, Treede RD. One night of total sleep deprivation promotes a state of generalized hyperalgesia: a surrogate pain model to study the relationship of insomnia and pain. *Pain* 2013; **154**: 1613-1621 [PMID: 23707287 DOI: 10.1016/j.pain.2013.04.046]

10 **O'Connor AB**, Dworkin RH. Treatment of neuropathic pain: an overview of recent guidelines. *Am J Med* 2009; **122**: S22-S32 [PMID: 19801049 DOI: 10.1016/j.amjmed.2009.04.007]

11 **Sindrup SH**, Otto M, Finnerup NB, Jensen TS. Antidepressants in the treatment of neuropathic pain. *Basic Clin Pharmacol Toxicol* 2005; **96**: 399-409 [PMID: 15910402 DOI: 10.1111/j.1742-7843.2005.pto\_96696601.x]

12 **Bourin M**, Chue P, Guillon Y. Paroxetine: a review. *CNS Drug Rev* 2001; **7**: 25-47 [PMID: 11420571 DOI: 10.1111/j.1527-3458.2001.tb00189.x]

13 **Duman EN**, Kesim M, Kadioglu M, Yaris E, Kalyoncu NI, Erciyes N. Possible involvement of opioidergic and serotonergic mechanisms in antinociceptive effect of paroxetine in acute pain. *J Pharmacol Sci* 2004; **94**: 161-165 [PMID: 14978354 DOI: 10.1254/jphs.94.161]

14 **Sindrup SH**, Bjerre U, Dejgaard A, Brøsen K, Aaes-Jørgensen T, Gram LF. The selective serotonin reuptake inhibitor citalopram relieves the symptoms of diabetic neuropathy. *Clin Pharmacol Ther* 1992; **52**: 547-552 [PMID: 1424428]

15 **Sindrup SH**, Gram LF, Brøsen K, Eshøj O, Mogensen EF. The selective serotonin reuptake inhibitor paroxetine is effective in the treatment of diabetic neuropathy symptoms. *Pain* 1990; **42**: 135-144 [PMID: 2147235 DOI: 10.1016/0304-3959]

16 **Ehde DM**, Kraft GH, Chwastiak L, Sullivan MD, Gibbons LE, Bombardier CH, Wadhwani R. Efficacy of paroxetine in treating major depressive disorder in persons with multiple sclerosis. *Gen Hosp Psychiatry* 2008; **30**: 40-48 [PMID: 18164939 DOI: 10.1016/j.genhosppsych.2007.08.002]

17 **Bockbrader HN**, Wesche D, Miller R, Chapel S, Janiczek N, Burger P. A comparison of the pharmacokinetics and pharmacodynamics of pregabalin and gabapentin. *Clin Pharmacokinet* 2010; **49**: 661-669 [PMID: 20818832 DOI: 10.2165/11536200-000000000-00000]

18 **van Seventer R**, Feister HA, Young JP, Stoker M, Versavel M, Rigaudy L. Efficacy and tolerability of twice-daily pregabalin for treating pain and related sleep interference in postherpetic neuralgia: a 13-week, randomized trial. *Curr Med Res Opin* 2006; **22**: 375-384 [PMID: 16466610 DOI: 10.1185/030079906X80404]

19 **Freynhagen R**, Strojek K, Griesing T, Whalen E, Balkenohl M. Efficacy of pregabalin in neuropathic pain evaluated in a 12-week, randomised, double-blind, multicentre, placebo-controlled trial of flexible- and fixed-dose regimens. *Pain* 2005; **115**: 254-263 [PMID: 15911152 DOI: 10.1016/j.pain.2005.02.032]

20 **Dworkin RH**, Corbin AE, Young JP, Sharma U, LaMoreaux L, Bockbrader H, Garofalo EA, Poole RM. Pregabalin for the treatment of postherpetic neuralgia: a randomized, placebo-controlled trial. *Neurology* 2003; **60**: 1274-1283 [PMID: 12707429 DOI: 10.1212/01.WNL.0000055433.55136.55]

21 **Solaro C**, Boehmker M, Tanganelli P. Pregabalin for treating paroxysmal painful symptoms in multiple sclerosis: a pilot study. *J Neurol* 2009; **256**: 1773-1774 [PMID: 19579001 DOI: 10.1007/s00415-009-5203-6]

22 Approval of SATIVEX with Conditions: Fact Sheet. 2005; Available at: http: //www.hc-sc.gc.ca/dhp-mps/prodpharma/notices-avis/conditions/sativex\_fs\_fd\_091289-eng.php. Accessed 08/08, 2013

23 **Polman CH**, Reingold SC, Edan G, Filippi M, Hartung HP, Kappos L, Lublin FD, Metz LM, McFarland HF, O'Connor PW, Sandberg-Wollheim M, Thompson AJ, Weinshenker BG, Wolinsky JS. Diagnostic criteria for multiple sclerosis: 2005 revisions to the "McDonald Criteria". *Ann Neurol* 2005; **58**: 840-846 [PMID: 16283615 DOI: 10.1002/ana.20703]

24 **Kurtzke JF**. Natural history and clinical outcome measures for multiple sclerosis studies. Why at the present time does EDSS scale remain a preferred outcome measure to evaluate disease evolution? *Neurol Sci* 2000; **21**: 339-341 [PMID: 11441569 DOI: 10.1007/s100720070047]

25 **Huitema BE.** Analysis of covariance and alternatives statistical methods for experiments, quasi-experiments, and single-case studies. Hoboken, N.J.: Hoboken, N.J. : Wiley; 2011

26 **Geisser ME**, Clauw DJ, Strand V, Gendreau RM, Palmer R, Williams DA. Contributions of change in clinical status parameters to Patient Global Impression of Change (PGIC) scores among persons with fibromyalgia treated with milnacipran. *Pain* 2010; **149**: 373-378 [PMID: 20332060 DOI: 10.1016/j.pain.2010.02.043]

27 **Kutner M,** Nachtsheim C, Neter J, Li W. Applied Linear Statistical Models. 5th ed. New York, NY: McGraw-Hill; 2005

28 **R Core Team.** R: A language and environment for statistical computing. 2013; Available at: http: //www.R-project.org/. Accessed 06/24, 2013.

29 **Diggle P,** Heagerty P, Kung-Yee L, Zeger S. Analysis of Longitudinal Data. 2nd ed. Oxford, New York: Oxford University Press; 2002.

30 **Cohen J.** Statistical power analysis for the behavioral sciences. 2nd ed. Hillsdale, New Jersey: Erlbaum Associates; 1988

31 **Cardenas DD**, Nieshoff EC, Suda K, Goto S, Sanin L, Kaneko T, Sporn J, Parsons B, Soulsby M, Yang R, Whalen E, Scavone JM, Suzuki MM, Knapp LE. A randomized trial of pregabalin in patients with neuropathic pain due to spinal cord injury. *Neurology* 2013; **80**: 533-539 [PMID: 23345639 DOI: 10.1212/WNL.0b013e318281546b]

32 **Achar A**, Chakraborty PP, Bisai S, Biswas A, Guharay T. Comparative study of clinical efficacy of amitriptyline and pregabalin in postherpetic neuralgia. *Acta Dermatovenerol Croat* 2012; **20**: 89-94 [PMID: 22726281 DOI: 10.4103/0378-6323.58686]

33 **Yamazaki Y**, Hata H, Kitamori S, Onodera M, Kitagawa Y. An open-label, noncomparative, dose escalation pilot study of the effect of paroxetine in treatment of burning mouth syndrome. *Oral Surg Oral Med Oral Pathol Oral Radiol Endod* 2009; **107**: e6-11 [PMID: 18996028 DOI: 10.1016/j.tripleo.2008.08.024]

34 **Sakpal T.** Sample size estimation in clinical trial. [*Perspect Clin Res*](http://www.ncbi.nlm.nih.gov/pubmed/?term=Sakpal+T.+Sample+size+estimation+in+clinical+trial) 2010; **1:** 67-9 [PMID: 21829786]

**P-Reviewers:**  Ajmal M, Tong C, Wang FZ **S-Editor:** Song XX **L-Editor:** **E-Editor:**



**Figure 1** **Study schedule summary.** Patient screening outcomes and visit schedule summaries are provided. Bracketed information on specified “Assessment” lines indicates evaluations conducted at each visit. NPP: Neuropathic pain; ICF: Informed consent form; EDSS: Expanded Disability Status Scale; PGIC: Patient Rated Global Impression of Change.

**Figure 2** **Patient-reported reasons for study attrition: paroxetine arm.** Patient-reported reasons for attrition are presented (*n* = 7). Patients were permitted to cite multiple reasons for treatment discontinuation. “Other” included complaints of feeling “shaky”, “caffeinated”, “jittery” and “anxious”.



**Figure 3** **Attrition by study group.** Attrition rates (shown in the format of survival distribution by study day) for each group (paroxetine and pregabalin) are presented. The average study duration (days) for paroxetine = 27.3 and for pregabalin = 49.5.

**Table 1** **Study eligibility requirements**

|  |  |
| --- | --- |
| Inclusion criteria | Exclusion criteria |
| males and females 18-65 years oldClinically definite RRMSEDSS ≤ 6.5VAS score for NPP symptoms > 5pain present for at least 3 moNegative serum pregnancy test | BreastfeedingHistory of alcohol or other substance abuseSignificant hepatic/renal insufficiencySignificant cardiac disease (CHF, arrhythmia); hypertensionHypersensitivity/allergy to study medications or their derivativesNo current therapeutic duplicationsNo history of psychotic/non-psychotic emotional disorders |

Inclusion and exclusion criteria for enrolment in the study are noted above. RRMS: Relapsing-remitting multiple sclerosis; EDSS: Expanded Disability Status Scale; NPP: Neuropathic pain; VAS: Visual analogue scale; CHF: Congestive heart failure.

**Table 2 Paroxetine/Pregabalin flexible-dose titration schedule**

|  |  |
| --- | --- |
| **Schedule** | **Dosage** |
| **Paroxetine** | **Pregabalin** |
| Day 1 | 20 mg once daily | 75 mg twice daily |
| Day 8 | 40 mg once daily | 150 mg twice daily |
| Day 15 | 50 mg once daily | 300 mg twice daily |

Flexible-dose titration schedule for each group is presented. Assuming therapy was well-tolerated patients were instructed to increase dosages as indicated above. If, however, at any point patients experienced intolerable side effects they were instructed to contact study investigators for tailored dosing instructions.

**Table 3 Study patient characteristics**

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
|  | Total | Paroxetine | Pregabalin | *P* value |
| NDemographicAge: mean (SD)Sex: % female | 2245.7(12.49)81 | 1043.1(12.85)90 | 1148.1(12.28)72.7 | n/a0.374NS |
| ClinicalEDSS: mean (SD)Baseline Pain: mean (SD)Duration of pain (mo): mean (SD)Time since MS diagnosis (years): mean (SD)  | 2.3(1.44)71.5(10.66)25.75(19.77)9.39(8.63) | 2.6(1.29)68.3(10.11)22.5(19.72)7.8(8.79) | 1.9(1.57)74.7(10.73)29(20.31)11.38(8.57) | 0.340.190.480.40 |
| Analysis% withdrawal from studyAverage final daily dose (mg) attained (% of maximum possible) | 40.9n/a | 7031 (62) | 18.2422.7 (70.5) | <0.001n/a |

Baseline characteristics–categorized as either “demographic” or “clinical”-are presented collectively for all patients combined (*n* = 22) as well as individually for paroxetine(*n* = 10) and pregabalin(*n* = 11) patient groupings. Where appropriate, mean and SD are provided. “Analysis” subheading provides information on the number of patients who withdrew prematurely from the study (“% withdrawal from study”) by group as well as the final average daily dose attained in each group. *P* values have been provided to estimate equivalence of groups. EDSS: Expanded Disability Status Scale; NS: No significant; n/a: Not available.

**Table 4** **Average study duration (days) by study group**

|  |  |
| --- | --- |
|  | Average Study Duration by Group (d) |
| N | Mean days in study | SD | Range of values |
| Lower  | Upper |
| Paroxetine | 10 | 27.3 | 21.6 | 5 | 58 |
| Pregabalin | 11 | 49.5 | 15.7 | 14 | 63 |

The mean duration of participation in the study by group is presented, with associated SD and range; Independent t-test between groups, *P* < 0.01.

**Table 5** **Univariate comparison results: VASpain and VASimpact**

|  |  |  |
| --- | --- | --- |
|  | **VASpain** | **VASimpact** |
| RR | RR |
| Group | 8.727 | 3.427 |
| Day | 0.5036 | 0.5065 |
| Group x Day | 0.1513 | 0.1918 |

# Univariate comparison results are presented on data from study participants completing the study. No significant findings were noted between comparisons. RR: Relative risk.